It will be interesting to see if I continue detecting Price Change Parity, as we had again today with shocking results for all the relevant companies noted in my post.
Two other things I want to talk about. The sotrovimab post I made earlier today, and the open Controlled Equity Offering.
The European Commission granted sotrovimab Marketing Authorization today. VIR and GSK had already secured 'a Joint Procurement Agreement (JPA) with the EC to supply up to 220,000 doses of sotrovimab. Following the grant of the marketing authorization in the EU, Member States participating in the JPA can now order sotrovimab to support their pandemic responses.' So Authorization was already priced in to VIR, and they basically closed unchanged.
There was no response to my sotrovimab post. But I think the post was more than just a game-changer for us. It's Revelation for HGEN, or it will be.
"...according to David Kessler, chief scientific officer of the White House covid-19 response team...
When omicron becomes dominant, it is expected to wipe out or weaken much of the covid-19 medicine cabinet, putting the focus on sotrovimab, which is an intravenous infusion from Vir Biotechnology and GlaxoSmithKline. Laboratory studies have shown that the treatment will hold up against the new variant. Antiviral pills that have yet to be authorized are also expected to help fill in the gaps..."
If the government is desperate enough to also be considering the use unauthorized, mutant-developing antiviral pills, they have to look at variant agnostic lenzilumab, designed to actually treat hospitalized patients. The revealed truth is that the vaccines are worthless in this regard, as are therapeutics, with the exception of late-stage toci. And we have the intellectual property rights, in part with Mayo, to lenz. So I hope to hear that Cameron has been in discussion with Mr. Kessler to provide lenz to the US government, even if the product, like the anti-viral pills, is not yet authorized.
Finally, I think our volume was the 4th highest in our history. A total of 23.5M shares, with 11M of that traded in the closing minutes. The average price was probably close to $4.50, so we are looking at a possible $50M trading period. That could have been provided from the balance of shares available in our Controlled Equity Offering.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.